EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference
03 Fevereiro 2016 - 12:00PM
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company
focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs), today announced that
the Company is scheduled to participate in a fireside chat at the
LEERINK Partners
5th Annual Global Healthcare Conference in New
York City on Wednesday, February 10, 2016 at 11:30 a.m. ET.
The link to the live audio webcast and replay of
the presentation may be accessed on the EPIRUS' website at
http://ir.epirusbiopharma.com/events.cfm. The webcast will be
archived on the Company's website for a period of three
months.
About EPIRUS
BiopharmaceuticalsEPIRUS
Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical
company focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve
global patient access to important, cost-effective medicines.
EPIRUS' current pipeline of biosimilar product candidates
includes: BOW015 (infliximab, reference biologic
Remicade®); BOW050 (adalimumab, reference biologic
Humira®); BOW070 (tocilizumab, reference biologic
Actemra®); BOW080 (eculizumab, reference biologic
Soliris®); BOW090 (ustekinumab, reference biologic
STELARA®); and BOW100 (golimumab, reference biologic
SIMPONI®)ii. The reference products for these candidates together
generated approximately $29.2 billion in global sales for
2014, according to EvaluatePharma®. EPIRUS has established multiple
partnerships to support its regulatory and commercialization
efforts in global markets. For more information visit EPIRUS'
website at www.epirusbiopharma.com.
Contact Information:
For media inquiries:
Mike Devine, FleishmanHillard
+1-212-453-2324
michael.devine@fleishman.com
For investor inquiries:
Marek Ciszewski, J.D.
EPIRUS Biopharmaceuticals
+1-617-553-9716
mciszewski@epirusbiopharma.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre EPIRUS Biopharmaceuticals Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de